Table 2.
Comprehensive comparative analysis of vaccination responses in patients and healthy controls
| Variable | N | Healthy control, n = 91 |
Lymphoid neoplasms, n = 42 |
P value healthy vs lymphoid neoplasms∗ | Myeloid neoplasms, n = 88 |
P value healthy vs myeloid neoplasms∗ |
|---|---|---|---|---|---|---|
| Spike-specific IgG detectable (n [%] of participants†) | 219 | 90 (99%) | 32 (78%) | < .001 | 86 (99%) | 1 |
| Spike-specific IgG levels (U/mL)‡ | 208 | 1554 (433; 3079) | 222 (92; 2115) | .02 | 942 (144; 2384) | .11 |
| Spike-specific CD4+ T cells detectable (n [%] of participants†) | 221 | 67 (74%) | 30 (71%) | .8 | 47 (53%) | .005 |
| Spike-specific CD4+ T cells (cells per μL blood)‡ | 144 | 0.166 (0.093; 0.251) | 0.165 (0.061; 0.248) | .7 | 0.111 (0.075; 0.238) | .7 |
| Spike-specific CD4+ T-cells (% of CD4+ T-cells)‡ | 144 | 0.012 (0.008; 0.02) | 0.024 (0.007; 0.035) | .12 | 0.018 (0.010; 0.027) | .26 |
| Activated CD4+ T cells by SEB detectable (n [%] of participants†) | 221 | 81 (89%) | 41 (97.6%) | .2 | 80 (91%) | .8 |
| Activated CD4+ T cells by SEB (cells per μL blood)‡ | 202 | 9.9 (3.9; 17.3) | 6.9 (4.3; 14.7) | .6 | 5.7 (2; 9.8) | .009 |
| Activated CD4+ T cells by SEB (% of CD4+)‡ | 202 | 0.82 (0.47; 1.25) | 1.71 (0.77; 2.81) | < .001 | 0.55 (0.34; 1.20) | .24 |
| Spike-specific CD8+ T-cells detectable (n [%] of particpants†) | 221 | 38 (42%) | 13 (31%) | .3 | 25 (28%) | .08 |
| Spike-specific CD8+ T cells (cells per μL blood)‡ | 76 | 0.038 (0.022; 0.085) | 0.035 (0.015; 0.057) | .5 | 0.050 (0.019; 0.168) | .5 |
| Spike-specific CD8+ T cells (% of CD8+)‡ | 76 | 0.008 (0.005; 0.017) | 0.009 (0.004; 0.012) | .9 | 0.014 (0.005; 0.027) | .4 |
| Activated CD8+ T cells by SEB detectable (n [%] of participants†) | 221 | 82 (90.1%) | 41 (97.6%) | .2 | 82 (93.2%) | .6 |
| Activated CD8+ T cells by SEB (cells per μL blood)‡ | 205 | 4 (1.9; 7.4) | 4.4 (2.7; 8.9) | .5 | 3 (0.9; 7.3) | .2 |
| Activated CD8+ T cells by SEB (% of CD8+)‡ | 205 | 0.86 (0.36; 1.50) | 1.15 (0.59; 2.01) | .14 | 0.76 (0.26; 1.65) | .6 |
Significant (<0.05) P values are highlighted in bold.
P values calculated using Dunn post hoc test (continuous data) or Fisher exact test (categorical data).
Numbers and percentages of participants who show a response in spike-specific IgG, CD4+ T cells, and CD8+ T cells as well as in SEB-activated CD4+ T cells and CD8+ T cells are tabulated by patient and control groups.
Spike-specific IgG levels are provided in U/mL, spike-specific and SEB-activated CD4+ T cells and CD8+ T cells, respectively, are provided as percentage of the respective T-cell subpopulations and as counts of polyfunctional T cells per μL blood (medians, Q1 and Q3). These data were calculated based upon all participants with detectable IgG, polyfunctional CD4+ T cells, and CD8+ T cells, respectively.